Medicalization Critiques

The rapid growth of psychedelic-assisted therapy as a recognized treatment modality has been accompanied by a set of critiques that merit serious attention - not as reflexive opposition to the field, but as honest engagement with the assumptions and priorities embedded in how medicalization proceeds. These critiques come from researchers within the field, from sociologists of medicine, from advocates for broader drug policy reform, and from indigenous communities whose traditional knowledge underlies much of the current clinical practice.

One central critique concerns reductionism: the concern that translating psychedelic healing into clinical protocols necessarily strips away dimensions of the experience that are therapeutically essential. The meaning-making framework, the relational container, the cosmological context - these are not decorative. Some researchers argue that they may be primary therapeutic agents, and that their removal in the interest of standardization and scalability produces an inferior version of what traditional and ceremonial practices offer.

A related critique targets the individualization of what has historically been a communal practice. Clinical protocols focus on the individual patient, their individual pathology, and their individual outcomes. Traditional healing practices typically understand distress as relational and communal: the individual is healed within and through the healing of their relational fabric. This is not simply a philosophical preference; some outcomes that are difficult to achieve through individual therapy become more accessible when healing happens in community.

Structural critiques point to who benefits from medicalization economically. The clinical infrastructure required to deliver MDMA-assisted therapy - two licensed therapists for an eight-hour session - makes this a premium service that will be difficult to deliver at anything approaching population scale. Intellectual property concerns (proprietary drug formulations and delivery methods) further concentrate economic benefit among a small number of actors.

Finally, indigenous scholars and advocates note that the research base is being built on millennia of indigenous knowledge and practice, largely without adequate attribution, compensation, or governance participation.

These critiques do not require abandoning the medical framework. They require that its development be undertaken with more honesty about what is being gained, what is being lost, and whose interests are being served.